# Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia

> **NCT03176771** · PHASE2,PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 256 (actual)

## Conditions studied

- Tardive Dyskinesia

## Interventions

- **DRUG:** MT-5199
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03176771
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-21
- **Primary completion:** 2020-09-29
- **Final completion:** 2020-09-29
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03176771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03176771, "Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03176771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*